Skip to main content

1. Al-Batran SE, Hartmann al: Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)
for patients with metastatic adenocarcinoma of the stomach or oesophagogastric junction: a phase II
trial of the Arbeitsgerneinschaft Intermistische Onkologie. Ann Oncol. 2008. Nov;19(11):1982-7.
2. Al-Batran SE, Hartmann al: Phase III trial metastatic gastroesophageal adenocarcinoma with
fluorouracil, leucovorin plus either oxaliplatin or cisplatin a study of the Arbeitsgemeinschaft
Intermistische Onkologie. J Clin Oncol 2008. May 20:2(9):1436-42.
3. Bonassi S, Norppa al: Chromosomal aberration frequency in lymphocytes predicts the risk of cancer
results from a pooled cohort study of 22 358 subjects in 11 countries. Carcinogenesis. 2008. jun; 29(6):
4. Cangiano J, Centeno al: Signal transduction proteins in tumors from Puerto Rican and Caucasian
gastric adenocarcinoma patients expression differences with potential for specific targeted therapies.
Dig Dis Sci.2008.Aug;53(8):2090-100.
5. Cho H, Tsuburaya al: A randomized phase II trial of preoperative exercise to reduce operative risk
in gastric cancer patients with metabolic syndroma: adjuvant exercise for general elective surgery (AEGES)
study group. Jpn J Clin Oncol. 2008. Jan; 38(1):71-3.
6. Cho H, Tsuburaya al: A randomized phase II trial of preoperative exercise to reduce operative risk
in gastric cancer patients with metabolic syndrome: adjuvant exercise for general elective surgery
(AEGES) study group. Jpn J Clin Oncol. 2008. Jan;38(1):71-3.
7. Cisco RM, Norton JA: Hereditary diffuse gastric cancer: surgery, surveillance and unanswered questions.
Future Oncol. 2008. Aug. 4(4),553-9.
8. Crusius JB, Canzian al: Cytokine gene polymorphisms and the risk of adenocarcinoma of the
stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST) Ann
Oncol. 2008. Nov;19(11)_1894-902.
9. Cunningham D, Staring al: Capecitabine and oxaliplatin for advanced esophagogastric cancer.
N Engl J Med. 2008.Jan 3;358(1):36-46.
10. Dank M, Zaluski al: Randomized phase III study comparing irinotecan combined with 5-fluorouracil
and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced
adenocarcinoma of the stomach or exophagogastric junction. Ann Oncol 2008.Aug; 19(8):1450-7.
11. Di Costanzo F,Gasperioni al: Adjuvant chemotherapy in completely resected gastric cancer a
randomized phased III trial conducted by GOIRC. J.Natl Cancer Inst. 2008 Mar 19; 100(6):388-98.
12. Drognitz O, Henne al: Long-term results after intraoperative radiation therapy for gastric cancer.
Int J Radial.Oncol Biol.Phys. 2008. Mar 1;70(3):715-21.
13. Fan YJ, Song al: Esophageal and gastric cardia cancers on 4238 Chinese patients reading in municipal
and rural regions: a histopathological comparison during 24-year period.. Word J Surg. 2008.Sep;32(9):1980-8.
14. Farran L, Liop al: Efficacy of enteral decontamination in the prevention of anastomotic dehiscence
and pulmonary infection in esophagogastric surgery. Dis Esophagus.2008;21(2);159-64.
15. Feng GS, MA al: Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized
Gastro 2009.qxd 5/9/2009 1:41 PM Page 135
136 Gastro Update 2009
trial for gastric cancer prevention. World J Gastroenterol. 2008:Jul 28;14(28);4535-9.
16. Feng Y, Zhang al: Inflammatory cytokine gene polymorphisms in gastric cancer cases and controls
family members from Chinese areas at high cancer prevalence. Cancer Lett.2008.Nov 8;270(2):250-9.
17. Galateros G, Simatos G, et al: Stromal tumors of the stomach,: a clinicopathological study of 15 cases
and review of the literature. Tumori. 2008. Jul-Aug:94(4);459-63.
18. Hamaguchi T, Shirao al: A phase II study of sequential methothrexate and 5-fluorouracil
chemotherapy in previously treated gastric cancer a report from the Gastrointestinal Oncology Group.
JCOG 9207 trial. Jpn J Clin Oncol. 2008.Jun;38(6):432-7.
19. Hamaguchi T, Sirao al: A phase I study of sequential methothrexate and 5-fluorouracil chemoterapy
in previously treated gastric cancer a report from the Gastrintestinal Oncology Group of the Japan Clinical
Oncology Group; JCOG 9207 trial. Jpn J.Clin Oncol. 2008.Jun;38(6):432-7.
20. Hejna M, Raderer al: Phase II study of docetaxel in combination with oxaliplatin in patients with
metastatic or locally andvanced esophagogastric cancer previously untreated with chemotherapy for
advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS 1.2.001.
Anticancer Drugs. 2008.Jun;19(5):535-9.
21. Huguet KL, Rush RM Jr. et al: Laparoscopic gastric gastrointestinal stromal tumor resection: the Mayo
Clinic experience. Arch Surg.2008.Jun;143(6):587-90.discussion 691.
22. Hwang J, Cho SH. et al: Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination
chemotherapy in patients with advanced gastric cancer. J Korean Med Sci.2008.Aug;23(4);586-91.
23. Hwang J, Cho al: Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination
chemotherapy in patients with advanced gastric cancer. J Korean Med Sci. 2008.Aug;23(4):586-91.
24. Hwang WS, Chao al: Phase II study of oxaliplatin in combination with continuous infusion of
5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Anticancer
Drugs. 2008.Mar;19(3):283-8.
25. Jatoi A, Daknil al: Bortezomib, paclitaxel and carboplatin as a first-line regimen for patients with
metastatic esophageal, gastric and gastroesophageal cancer phase II results from the North Central Cancer
Treatment Group (N0448) J Thorac Oncol 2008.May;3(5):516-20.
26. Jeong J, Jeung al: Phase II study of combination chemotherapy of 5-fluorouracil low-dose
leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. Ann Oncol.
27. Kang HJ, Chang HM. et al: A phase II study of paclitaxel and capecitabine as a first-line combination
chemotherapy for advanced gastric cancer. Br.J Cancer. 2008.Jan 29;98(2):316-22.
28. Karin-Kos HE, de Vries al: Recent trends of cancer in Europe: a combined approach of incidence,
survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008.Jul;44(10):1345-89.
29. Keam B, Im al: Modified FOLFOX-6 chemotherapy in advanced gastric cancer. Results of phase II
study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC
30. Kim JG, Sohn al: Chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk
Oncology Group. Br J Cancer. 2008.Feb 12;98(3):642-6.
31. Kim MC, Kim al: Risk factors associated with complication following laparoscopy-assisted
gastrectomy for gastric cancer: a large-scale Korean multicenter study. Ann Surg.Oncol. 2008
32. Kim N, Park al: Helicobacter pylori infection and development of gastric cancer in Korea long-term
follow-up. J Clin Gastoenterol 2008.May-Jun;42(5):448-54.
Gastro 2009.qxd 5/9/2009 1:41 PM Page 136
A gyomor 137
33. Kim YH, Seo al: Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination
chemotherapy for advanced gastric cancer. Cancer Chemother Pharmazol. 2009.jan;63(2):253-60.
34. Koizumi W, Okayasu I. et al: Prediction of the effect of capecitabine in gastric cancer by immunohistochemical
staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Anticancer
35. Koizumi W, Narahara al: S-1 cisplatin versus S-1 alone for first-line treatment of advanced gastric
cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008.Mar;9(3):215-21.
36. Kozak KR, Moody JS.: The survival impact of the intergroup 0116 trial on patients with gastric cancer.
Int J Radiat Oncol Biol Phys.2008 Oct 1;72(2):517-21.
37. Leung WK, Wu MS. Et al: Screening for gastric cancer in Asia: current evidence and practice. Lancet
Oncol 2008.Mar;9(3):279-87.
38. Liu C, Sun Q. et al: Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in
Chinese patients with advanced gastric cancer. Anticancer Drugs. 2008.Sep;19(8);825-31.
39. Luo HY, Xu al: A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line
chemotherapy in advanced or recurrent gastric cancer. Chemotherapy 2008;54(3):228-35.
40. Matsubara J, Shimada al: A phase of bolus 5-fluorouracil and leucovorin combined with
weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer. Jpn J.Clin.Oncol.
41. Matsubara J, Yamada al: Clinical significance of insulin-like growth factor type 1 receptor and epidermal
growth factor receptor in patients with advanced gastric cancer.Oncology.2008;74(1-2):76-83.
42. Nakayama N, Koizumi al: A multicenter, phase, I dose-escalating study of docetaxel, cisplatin and
S-1 for advanced gastric cancer (KDOG0601). Oncology. 2008;75(1-2)1-7.
43. Narahara H, al: Phase II study of a combination of S-1 and paclitaxel in patients with
unresectable or metastatic gastric cancer. Oncology.2008;74(1-2):37-41.
44. Navarro Silvera SA, Mayne al: Food group intake and risk of subtypes of esophageal and gastric
cancer. Int J Cancer.2008.Aug;15:123(4):852-60.
45. Park SH, Kim al: Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric
cancer: a non-comparative phase II study. Anticancer Drugs. 2008 Mar;19(3):303-7.
46. Park SR, Kim KH. et al: Phase I-II study of S-1 combined with weekly docetaxel in patients with
metastatic gastric carcinoma. Br J.Cancer 2008.Apr 22;98(9):1305-11.
47. Park SR, Lee al: Endoscopic ultrasound and computed tomography in restaging and predicting
prognosis after neoadjuvant chemoterapy in patients with locally advanced gastric cancer.
48. Persiani R, Rausei al: 7-Year survival results of perioperative chemotherapy with epidoxorubicin,
etoposide, and cisplatin (EEO) in locally advanced resectable gastric cancer: up-to-date analysis of a
phase-II study. Ann Surg Oncol. 2008.Aug;15(8):2146.52.
49. Sasako M., Sano T. et al: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric
cancer. N.Engl.J.Med.2008.Jul31;359(5);453-62.
50. Scott LC, Yao al: A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of
locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer
Chemoter Pharmacol. 2009. Jan:63(2):363-70.
51. Seo MD, Lee KW et al: Irinotecan combined with 5-fluorouracil and leucovorin as second-line
chemotherapy for metastatic or relapsed gastric cancer. Jpn J Clin Oncol. 2008.Sep;38(9);589-95.
Gastro 2009.qxd 5/9/2009 1:41 PM Page 137
138 Gastro Update 2009
52. Shin SJ, Jeung al: Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined
maximal tolerance dose and continuous infusional chemotherapy and G.CSF surge in gastric cancer.
Cancer Lett. 2008.Nov 8;270(2):269-76.
53. Sitas F, Parkin al: Part II. Cancer in indigenous Africans-causes and control. Lancet Oncol.
54. Song KY, Hyung WJ:et al: Is gastrectomy mandatory for all residual or recurrent gastric cancer following
endoscopic resection? A large-scale Korean multi-center study. J.Surg.Oncol. 2008.Jul 1;98(1):6-10.
55. Sym SJ, Chang al: A phase II study of irinotecan and docetaxel combination chemotherapy for
patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother
Pharmacol. 2008.Dec;63(1):1-8.
56. Tsuji A, Sima al: Combination chemoterapy of S-1 and low-dose twice-weekly cisplatin for
advanced and recurrent gastric cancer in an outpatient setting: a retrospective study. Anticancer Res.
57. Wang B, Zhang al: Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in
combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer. Cancer
Chemother Pharmazol. 2008.Nov;62(6):1076-83.
58. Yanaoka K, Oka al: Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after
10-year follow-up in asymptomatic middle-aged males. Cancer Epidermiol Biomarkers Prev. 2008.Apr;
59. Zhu X, Leaw al: Phase II clinical trial of advanced and metastatic gastric cancer based on continuous
infusion of 5-fluorouracil combined with epirubicin and oxaliplatin. J Cancer-Res Clin Oncol.